Bavarian Nordic A/S buy wiltrud
Summary
This prediction ended on 28.01.15 with a price of €26.80. With a performance of 7.98%, the BUY prediction by wiltrud for Bavarian Nordic A/S closed with a slight gain. wiltrud has 50% into this predictionBavarian Nordic (symbol: BAVA) is a biotechnology company that specializes in developing innovative vaccines for serious diseases such as cancer and infectious diseases like Ebola and COVID-19. The company has a broad portfolio of vaccines that are under development and has collaboration agreements with various pharmaceutical companies and government agencies. Bavarian Nordic's flagship product is its cancer vaccine known as PROSTVAC, which is currently undergoing clinical trials for the treatment of prostate cancer. The company is listed on the NASDAQ Copenhagen stock exchange and has a market capitalization of approximately $925 million as of May 2021.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Bavarian Nordic A/S | 12.261% | 12.261% | -10.770% | -32.848% |
| iShares Core DAX® | 0.238% | -2.265% | 13.679% | 14.917% |
| iShares Nasdaq 100 | -0.304% | 5.808% | 34.538% | 52.796% |
| iShares Nikkei 225® | 2.271% | 1.577% | 9.436% | 5.432% |
| iShares S&P 500 | -0.296% | 4.447% | 28.577% | 47.257% |
Comments by wiltrud for this prediction
In the thread Bavarian Nordic A/S diskutieren
Fokus im Bereich Impfstoffe
Bavarian Nordic A/S ist ein Unternehmen aus den Branchen Biotech und Pharma aus Dänemark.
Stellt unter anderem Pockenimpfstoff für die USA her.
Ist auch in der Entwicklung von Ebolaimpfstoff beteiligt zusammen mit Johnson & Johnson
http://globenewswire.com/news-release/2014/09/04/663599/10097177/en/Bavarian-Nordic-Accelerates-Ebola-Vaccine-Development-Programs-in-Collaboration-with-the-U-S-National-Institutes-of-Health.html?parent=663855
Stopped prediction by wiltrud for Bavarian Nordic A/S
Bavarian Nordic A/S
04.03.15
17.04.15
17.04.15
